Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGT-182 in Hunter Syndrome
NCT02262338Phase 1Completed
- Sponsor
- ArmaGen
- Start
- Apr 2015
- Primary completion
- Mar 2017
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of AGT-182 in mucopolysaccharidosis type II, sponsored by ArmaGen. Primary endpoint: Number of participants with adverse events at 13 weeks. Started Apr 2015; status: completed.
02
Drugs
AGT-182
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT02262338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262338.